The stock of Check Cap Ltd (NASDAQ:CHEK) is a huge mover today! About 154,005 shares traded hands. Check Cap Ltd (NASDAQ:CHEK) has declined 3.33% since April 18, 2016 and is downtrending. It has underperformed by 7.76% the S&P500.
The move comes after 8 months negative chart setup for the $36.37M company. It was reported on Nov, 18 by Barchart.com. We have $2.39 PT which if reached, will make NASDAQ:CHEK worth $4.00M less.
Check Cap Ltd (NASDAQ:CHEK) Ratings Coverage
Out of 2 analysts covering Check-Cap (NASDAQ:CHEK), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Check-Cap has been the topic of 5 analyst reports since July 22, 2015 according to StockzIntelligence Inc. Chardan Capital Markets maintained Check Cap Ltd (NASDAQ:CHEK) on Wednesday, July 22 with “Buy” rating. The stock has “Buy” rating given by Maxim Group on Thursday, October 8. The rating was maintained by Chardan Capital Markets on Wednesday, March 16 with “Buy”. Maxim Group maintained Check Cap Ltd (NASDAQ:CHEK) on Tuesday, January 19 with “Buy” rating. The stock of Check Cap Ltd (NASDAQ:CHEK) earned “Buy” rating by Chardan Capital Markets on Friday, May 20.
According to Zacks Investment Research, “Check Cap Ltd. is a medical diagnostics company. The company is engaged in the development of an ingestible imaging capsule for the screening of colorectal cancer. Check Cap Ltd. is based in Mount Carmel, Israel.”
More important recent Check Cap Ltd (NASDAQ:CHEK) news were published by: Prnewswire.com which released: “Check-Cap Ltd. Announces $5.9 Million Financing” on August 08, 2016, also Quotes.Wsj.com published article titled: “Check-Cap Ltd. CHEK (US: Nasdaq)”, Marketwatch.com published: “Check-Cap stock price target cut to $6 from $11 at Maxim Group” on March 20, 2015. More interesting news about Check Cap Ltd (NASDAQ:CHEK) was released by: Prnewswire.com and their article: “Check-Cap Announces Appointment of William Densel as Chief Executive Officer …” with publication date: August 13, 2015.
CHEK Company Profile
Check-Cap Ltd. (Check-Cap), incorporated on April 5, 2009, is a clinical-stage medical diagnostics company. The Firm is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC) work station for data reconstruction and image processing.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.